Effects of Ectinib combined with Endu on the efficacy and prognosis of EGFR-mutation-posi-tive lung adenocarcinoma patients
Aim To observe the clinical efficacy and prognosis of Ectinib combined with Endu in the treatment of epidermal growth factor receptor(EGFR)mutation-positive lung adenocarcinoma.Methods 124 patients with advanced EGFR-mutation-positive lung adenocarcinoma were retrospectively selected as the study subjects,and were divided into Ectinib group(Ectinib alone)and Endu combined group(Ectinib combined with Endu)according to the treatment plan of the patients.The levels of tumor markers and immune function indexes were compared between the two groups before treatment and after 4 cycles of treatment.The short-term curative effects of the two groups were evaluated.The occurrence of adverse reactions during treatment was observed in the two groups.Kaplan-Meier method was used to compare long-term curative effects of the survival curves of progression-free survival(PFS)and overall survival(OS)between the two groups.Results After 4 cycles of treatment,the levels of tumor indexes and CD8+in two groups were significantly lower than them before treatment(P＜0.05),and Endu combined group was lower than Ectinib group(P＜0.05).The levels of CD3+,CD4+,CD4+/CD8+in both groups were higher than them before treatment(P＜0.05),and Endu combined group was higher than Ectinib group(P＜0.05).The OS of the Endu combination group was longer than that of the Ecetinib group(P＜0.05).There was no significant difference in recent efficacy,PFS,and adverse reactions between the two groups of patients(P＞0.05).Conclusion The second-line treatment regimen of Ecetinib combined with Endu can help improve the overall survival of EGFR mutation positive lung adenocarcinoma patients and is safe.
万方数据
维普
